Melphalan
Formulations: - Parenteral > General injections > IV: 50 mg in vial powder for injection Oral > Solid: 2 mg Indications: - Plasma cell myeloma Source: EML workbook import
Imported from EML workbook.
Formulations: - Parenteral > General injections > IV: 50 mg in vial powder for injection Oral > Solid: 2 mg Indications: - Plasma cell myeloma Source: EML workbook import
Formulations: - Oral > Solid: 50 mg tablet Oral > Liquid: 20 mg per mL Indications: - Unspecified malignant neoplasms of ill-defined or unspecified sites - Lymphoid leukaemia, not elsewhere classified - Acute myeloid leukaemia with recurrent genetic abnormalities - Langerhans cell histiocytosis Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial Indications: - Malignant neoplasm metastasis in large intestine - Malignant neoplasms of colon Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 6 mg per mL Indications: - Other specified malignant neoplasms of the ovary - Other specified malignant neoplasms of bronchus or lung - Malignant neoplasms of nasopharynx - Kaposi sarcoma of unspecified primary site - Other specified malignant neoplasms of breast - Other specified carcinomas of ovary - Malignant neoplasms of breast - Malignant neoplasms of cervix uteri Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection Indications: - Lymphoid leukaemia, not elsewhere classified Source: EML workbook import
Formulations: - Oral > Solid: 50 mg (as hydrochloride) Oral > Solid > capsule: 50 mg (as hydrochloride) Indications: - Unspecified malignant neoplasms of ill-defined or unspecified sites - Hodgkin lymphoma Source: EML workbook import
Formulations: - Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg) Indications: - Acute myeloid leukaemia with recurrent genetic abnormalities Source: EML workbook import
Formulations: - Oral > Solid: 40 mg Indications: - Lymphoid leukaemia, not elsewhere classified Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate) Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate) Indications: - Unspecified malignant neoplasms of ill-defined or unspecified sites - Other specified gliomas of brain - Hodgkin lymphoma - Other specified malignant neoplasms of the ovary - Germ cell tumour of testis - Kaposi sarcoma of unspecified primary site - Anaplastic large cell lymphoma, ALK-negative - Anaplastic large cell lymphoma, ALK-positive - Langerhans cell histiocytosis Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate) Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate) Indications: - Unspecified malignant neoplasms of ill-defined or unspecified sites - Other specified gliomas of brain - Follicular lymphoma - Malignant trophoblastic neoplasms of placenta - Diffuse large B-cell lymphoma, not otherwise specified - Kaposi sarcoma of unspecified primary site - Rhabdomyosarcoma primary site - Hodgkin lymphoma - Burkitt lymphoma including Burkitt leukaemia - Ewing sarcoma of bone and articular cartilage of unspecified sites - Malignant neoplasms of kidney, except renal pelvis - Lymphoid leukaemia, not elsewhere classified - Retinoblastoma - Langerhans cell histiocytosis Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial Oral > Solid > capsule: 20 mg; 30 mg; 80 mg Indications: - Other specified malignant neoplasms of bronchus or lung - Other specified malignant neoplasms of breast - Rhabdomyosarcoma primary site Source: EML workbook import
Ready to amplify your rewards? Drop your email and we'll be in touch soon.